The high prevalence of hypokalemia among patients with coronavirus disease 2019 suggests the presence of disordered rennin-angiotensin system activity, which is increased as a result of the reduced counteractivity of angiotensin-converting enzyme 2, which is bound by severe acute respiratory syndrome coronavirus 2. The gene discussed is ACE2; the disease is COVID-19.